It is well recognized that the renin-angiotensin system plays an important role in renal function as part of the system's overall control of water and salt homeostasis. The generation of angiotensin II (Ang II) from Ang I has long been considered the final product of this biological cascade. Ang II induces a variety of actions in the kidney including potent vasoconstriction of the renal microcirculation, release of aldosterone to stimulate sodium reabsorption, alteration of glomerular filtration, stimulation of sodium and bicarbonate transport in the proximal tubules and the promotion of mesangial cell hypertrophy [1] .
Recent studies have revived the possibility that angiotensin peptides other than Ang II may either contribute to or actually oppose the cardiovascular actions of Ang II, endowing this hormonal system with a greater flexibility than originally imagined. The characterization of Ang-(1-7) as the first amino terminal angiotensin peptide product possessing biological actions provided a foundation for the pursuit of a new concept regarding the regulation of cardiovascular function by the renin-angiotensin system. Indeed, the accumulating evidence suggests that Ang-(1-7) may serve to counterbalance the actions of Ang II [2] . This review updates the progress that has been made in the development of this concept by examining the renal actions of Ang-(1-7).
Tubular actions of Ang-(1-7)
Studies by Douglas and colleagues initially suggested that Ang-(1-7) might have important actions on the kidney. These authors found that Ang-(1-7) was more potent than Ang II to inhibit transcellular sodium flux in cultured renal tubular epithelial cells from rabbit [3] . The effects of Ang-(1-7) were associated with an activation of phospholipase A 2 . Moreover, they found that the inhibition of sodium transport with Ang I was markedly potentiated by the converting enzyme (ACE) inhibitor captopril. Proximal tubules are an abundant source of the endopeptidase neprilysin, which cleaves Ang I directly to Ang-(1-7) [4] . Thus, ACE inhibition may enhance Ang I to Ang-(1-7) formation and attenuate the metabolism of Ang-(1-7) [5] . Consistent with the natriuretic actions of the peptide in vitro, Ang-(1-7) infusion produced marked diuresis and natriuresis in the isolated [6] and intact kidney of Sprague Dawley (SD) and Wistar rats, respectively [7, 8] . In contrast to the potent vasoconstriction produced by Ang II, Ang-(1-7) lacked any effect on renal blood flow (RBF), nor did Ang-(1-7) antagonize the actions of Ang II on RBF [6, 8] . In a subsequent report, the diuretic actions of Ang-(1-7) in the isolated kidney were associated with increased prostacyclin in the urinary and venous effluent; the cycloxygenase inhibitor indomethacin attenuated the effects of the peptide [9] . That Ang-(1-7) stimulates prostaglandin release from the isolated kidney is consistent with the peptide's actions following chronic infusion in the spontaneously hypertensive rat (SHR, and to a lesser extent in WKY controls) [10] and various cell preparations [11] . In isolated convoluted proximal tubules, low doses (10 Ϫ13 to 10
of Ang-(1-7) inhibited transport-dependent oxygen consumption, a marker for Na ϩ ,K ϩ -ATPase activity [8] . Inhibition of this activity by Ang-(1-7) was partially blocked by an AT 1 antagonist and completely attenuated by the nonselective antagonist [Sarcosine 1 ,threonine while higher concentrations (10 Ϫ8 M) inhibited fluid absorption most probably by altering the affinity of the Na ϩ /H ϩ exchanger [12] . Both actions were completely blocked by losartan, and partially by PD123319.
The tubular actions of Ang-(1-7) are either partially or completely blocked by AT 1 antagonists; however, the peptide clearly lacks constrictive effects at renal or other vascular AT 1 receptor sites. These data suggest that Ang-(1-7) may distinguish multiple AT 1 receptor sites in the kidney. Recent studies by Santos and colleagues also indicate that Ang-(1-7) interacts with a novel AT 1 or losartan-sensitive site in the kidney [14 -16] . In waterloaded Wistar rats, Ang-(1-7) promotes an anti-diuretic action with a tendency for increased plasma vasopressin [13] . The anti-diuretic effects were attenuated by the AT 1 agent losartan and the Ang-(1-7) antagonist D- [Ala 7 ]-Ang-(1-7) [14] . Santos et al [15] have also reported that the peptide inhibits water transport in a collecting duct preparation, an effect blocked by the D-[Ala] antagonist. The D-[Ala]-Ang-(1-7) compound does not inhibit Ang II binding at either the AT 1 or AT 2 sites in the adrenal, nor attenuates the vasoconstrictor effects of Ang II [16] .
The anti-diuretic effects of Ang-(1-7) are in direct contrast to the effects observed in the isolated and in situ perfused kidney, or with chronic infusion in SHRs. One obvious difference in the studies with intact animals was that the experiments were performed after water loading. Burnier et al [17] reported conflicting results concerning AT 1 treatment of patients following an acute water load. These findings emphasize that the overall state of sodium and water balance (and perhaps the overall activity of the renin-angiotensin system) may be critically important in determining the effects of Ang-(1-7) in the kidney. Moreover, the route of administration, the site of the nephron exposed to Ang-(1-7), and the dose of the peptide may influence the direction of observed actions.
Ang-(1-7) may access the kidney through the circulation or by intra-renal generation. The biochemical components to yield Ang-(1-7) including renin, angiotensinogen, Ang I and neprilysin are present within the kidney, particularly within the proximal tubules. A potential insight into the role of Ang-(1-7) in renal function was gained by the demonstration of the heptapeptide in rat urine. As shown in Figure 1A , we compared the concentration of angiotensin peptides from renal tissue [18] and urine [19] in SD rats. In contrast to tissue, urinary levels of immunoreactive Ang-(1-7) are higher than those of Ang II, but comparable to Ang I. Analysis of urine extracts by high performance liquid chromatography (HPLC) revealed a predominant immunoreactive peak that corresponds to the Ang-(1-7) standard, with a smaller peak at a retention time corresponding to Ang-(3-7) (Fig. 1B) . To determine whether urinary Ang-(1-7) results from the proteolysis of Ang I in urine, we assessed the metabolism of 125 I-labeled Ang I, in pooled urine samples. HPLC analysis of 125 I-Ang I metabolism following a 30 minute incubation did not reveal the presence of either labeled Ang II or Ang- (1-7) ; only smaller peptide fragments were detected (Fig. 1C) . Inhibition of Ang I metabolism by the chelating agents EDTA and O-phenanthroline (OP) did not reveal the presence of Ang-(1-7) or Ang II, which suggests that excretion of Ang-(1-7) does not arise from the conversion of Ang I or Ang II to Ang-(1-7) by urinary peptidases, but from either tissue release of the peptide or the luminal processing of a precursor such as Ang I or Ang II. We have begun to address whether the excretion of Ang-(1-7) is under dynamic control or is constituitively secreted. A five-day treatment with lisinopril significantly increased the urinary excretion of both Ang I and Ang-(1-7) in SD rats (Fig. 2A) . Since we have shown that Ang-(1-7) is degraded by ACE, this effect may result from protection of Ang-(1-7) [5] . We and others have shown that plasma levels of Ang-(1-7) are markedly elevated following chronic treatment with ACE inhibitors [20 -22] . Although it is presently unknown 125 I-Ang I (0.5 nM) was incubated with rat urine for 30 minutes at 37°C in the presence (dashed line) or absence (solid line) of EDTA/ phenanthroline (OP; 1 mM each) and subjected to HPLC analysis as described [26] .
whether the increased urinary excretion of Ang-(1-7) contributes to the renal actions of ACE inhibitors, we have recently shown that Ang-(1-7) contributes to the antihypertensive effects of combined lisinopril/losartan in the SHR [23, 24] . In addition, the combined treatment with lisinopril and the orally active NEP inhibitor CGS 25460 lowered excretion of Ang-(1-7) to control levels, but further augmented Ang I and increased Ang II (Fig. 2A) .
Ang-(1-7) has been characterized in the urine from human subjects as well [25] . As shown in the bottom panel of Figure 2 , untreated essential hypertensive subjects exhibited a lower urinary excretion rate of Ang-(1-7) than normotensive controls [12.2 Ϯ 1.7 pmol Ang-(1-7) nmol creatinine Ϫ1 (Cr) 24 hours Ϫ1 versus 5.78 Ϯ 0.92 pmol Ang-(1-7) nmol Cr Ϫ1 24 hours Ϫ1 , respectively (P Ͻ 0.007]). Furthermore, urinary concentrations of Ang-(1-7) correlated inversely with arterial pressures (r ϭ Ϫ0.48, P Ͻ 0.001), while both urinary Ang-(1-7) (odds ratio 0.92; 95% CI, 0.88 to 0.97) and age were independent predictors of systolic blood pressure. The inverse association between Ang-(1-7) and arterial pressure may provide a potential marker for the characterization of forms of essential hypertension associated with reduced production or activity of diuretic/natriuretic hormones.
SUMMARY
Studies of the effects Ang-(1-7) in the kidney suggest that the renin-angiotensin system possesses the ability to either limit or possibly promote sodium and water excretion through the alternative processing of Ang I. Further studies are necessary to clearly establish the role of Ang-(1-7) in physiologic and pathophysiologic conditions. In this regard, the use of more selective agents to delineate the actions of Ang-(1-7) from those of Ang II will be critically important to resolve the renal actions of Ang-(1-7). 
